[Question] Ireland — has anyone got a straight answer on 503B
Ireland — has anyone got a straight answer on 503B. If this has been answered properly somewhere, link me and I will delete.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
a 503B has to register and report, so there is a paper trail to ask for
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
the price difference is mostly the intake, not the vial
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
What is the beyond-use date and what is it based on?
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
ask what the beyond-use date is based on
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
if a clinic will not name the facility, that is your answer
the label on a compounded vial is a legal document, read it
ask which facility, then ask for their testing
the pharmacy and the prescriber are two separate questions
What concentration is on the label, and does it match what you were expecting?
salt forms are the recurring argument and the answer is boring
a telehealth intake that asks nothing has told you what it is
shortage status changes and the whole arrangement changes with it
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
Who is the prescriber, and are they the same organisation as the pharmacy?
Is the compound still on the shortage list where you are?
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
- 1What concentration is on the label, and does it match what you were expecting?7 comments in this branch · started by u/pavel_kravchenko